Skip to content

Risk assessment of bleeding after gastric submucosal dissection in patients taking anticoagulant drugs and validity evaluation of supplemented guideline for gastrointestinal endoscopy in patients taking antithrombotic drugs: multicenter observational study

Risk assessment of bleeding after gastric submucosal dissection in patients taking anticoagulant drugs and validity evaluation of supplemented guideline for gastrointestinal endoscopy in patients taking antithrombotic drugs: multicenter observational study - Risk assessment of bleeding after gastric submucosal dissection in patients taking anticoagulant drugs and validity evaluation of supplemented guideline for gastrointestinal endoscopy in patients taking antithrombotic drugs: multicenter observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000050792
Enrollment
1740
Registered
2023-04-09
Start date
2023-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer

Interventions

None listed

Sponsors

National Hospital Organization Kyoto Medical Center
Lead Sponsor
Tokyo Medical University Kyoto Medical Center University of Tokyo Tohoku University National Cancer Center Hospital Fukushima Medical University Hospital University of Tsukuba Hospital Hirosaki University Toyonaka Municipal Hospital Jikei University Hospital National Center for Global Health and Medicine Konodai Hospital Hamamatsu University School of Medicine Tokyo Metropolitan Bokuto Hospital Iwate Medical University Seirei Hamamatsu Hospital Nihon University Kansai Rosai Hospi
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Those who are 20 years of age or older 2. Those who have undergone ESD treatment for early gastric cancer in accordance with the "Stomach Cancer Treatment Guidelines" edited by the Japan Gastric Cancer Society 3. Those taking anticoagulants (warfarin or DOAC) 4. Those who have undergone ESD treatment for early gastric cancer in accordance with the "Guidelines for Gastrointestinal Endoscopy for Patients Taking Antithrombotic Drugs" edited by the Japan Gastroenterological Endoscopy Society or its supplements.

Exclusion criteria

Exclusion criteria: 1. Patients who discontinued ESD or underwent surgical treatment due to complications (bleeding, perforation, etc.) or technical reasons during ESD. 2. Those who have not been able to follow up for more than 28 days after ESD 3. Subjects who received additional photodynamic therapy (PDT) after ESD 4. Patients with infiltration deeper than the muscle layer in histopathological evaluation of the resected specimen 5. Patients participating in other interventional trials 6. Those who refuse to use clinical data

Design outcomes

Primary

MeasureTime frame
Evaluation of the postoperative bleeding rate before and after the revised guideline in patients taking antithrombotic drugs during gastric ESD in patients taking anticoagulants.

Countries

Japan

Contacts

Public ContactMasaki Murata

National Hospital Organization Kyoto Medical Center Department of gastroenterology

mura05310531@gmail.com+81756419161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026